Genetic Testing for Breast Cancer

Understanding Genetic Testing for Breast Cancer

Breast cancer is the most commonly diagnosed cancer among women worldwide, affecting approximately 1 in 8 women over their lifetime in many Western countries. While most cases arise from a combination of environmental and lifestyle factors, a meaningful proportion — estimated between 5% and 12% — are driven substantially by inherited genetic mutations that significantly elevate a person's lifetime risk. For these individuals, knowing their genetic profile is not merely informative; it can be life-saving.

Genetic testing for breast cancer risk looks for specific inherited mutations — changes in the DNA sequence of genes that are passed from parent to child — that are associated with a higher-than-average probability of developing breast cancer, ovarian cancer, and in some cases other cancers. Understanding what these tests involve, who they are for, and how results translate into medical action is essential knowledge for anyone considering this type of screening.

The Genes at the Center: BRCA1 and BRCA2

The best-known and most clinically significant genes in hereditary breast cancer are BRCA1 (breast cancer gene 1) and BRCA2 (breast cancer gene 2). Both genes normally function as tumor suppressors — they help repair damaged DNA and prevent cells from dividing uncontrollably. When mutations disrupt these genes, the cell's repair machinery is compromised, allowing errors to accumulate and increasing the risk of cancer.

Beyond BRCA1 and BRCA2, modern multi-gene panel tests also screen for mutations in other genes with varying degrees of breast cancer risk elevation, including PALB2, CHEK2, ATM, BRIP1, RAD51C, RAD51D, and others. The clinical significance of many of these variants is still being characterized.

Who Should Consider Genetic Testing?

The most important indicator for genetic testing is personal and family history. The Centers for Disease Control and Prevention (CDC) and major oncology organizations recommend consideration of genetic evaluation for individuals who:

• Have a first-degree relative (parent, sibling, or child) diagnosed with breast cancer, particularly at age 50 or younger
• Have a personal or family history of bilateral breast cancer or male breast cancer
• Have a family history of ovarian, fallopian tube, or primary peritoneal cancer
• Are of Ashkenazi Jewish, Eastern European, or other founder-effect ancestry with a family history of breast or ovarian cancer
• Have a known BRCA1, BRCA2, or other pathogenic mutation in the family
• Have a personal history of breast cancer with triple-negative histology at age 60 or younger
• Have two or more relatives on the same side of the family with breast or related cancers

Building Your Family History

A thorough family history is the foundation of any risk assessment. When compiling yours:

• Include all first- and second-degree relatives: parents, grandparents, siblings, children, aunts, uncles, nieces, and nephews
• Record the type of cancer and the age at diagnosis for each relative
• Include both sides of the family — paternal history matters just as much as maternal
• Note any relatives with multiple primary cancers
• Update the record as new diagnoses occur within the family

How Genetic Testing Works

Genetic testing for hereditary breast cancer is straightforward from the patient's perspective. The process typically involves:

• Pre-test genetic counseling: A certified genetic counselor reviews personal and family history, explains what the test can and cannot reveal, and discusses implications of different possible results before testing begins.
• Sample collection: A saliva sample (collected by swabbing the inside of the cheek) or a blood draw is taken. Either is sufficient for DNA analysis.
• Laboratory analysis: The sample is sent to a specialized laboratory where the DNA is sequenced or analyzed for known pathogenic variants. Standard panels examine BRCA1 and BRCA2; extended panels analyze dozens of additional genes simultaneously.
• Results and interpretation: Results typically take 2 to 4 weeks. A second counseling session helps the individual understand what their results mean in practical terms.

Understanding Your Results

Genetic test results fall into three categories:

• Positive: A pathogenic or likely pathogenic variant was found. This means you carry an inherited mutation that increases your cancer risk. It does not mean you have cancer or will definitely develop it.
• Negative: No pathogenic variant was identified in the genes tested. If your test was triggered by a known family mutation and the test was targeted to that mutation, a negative result is highly reassuring. If tested based on family history alone, a negative result reduces but does not eliminate risk.
• Variant of uncertain significance (VUS): A variant was found, but current evidence is insufficient to classify it as harmful or benign. VUS findings require ongoing monitoring as scientific knowledge evolves.

Benefits of Genetic Testing

• Relief from uncertainty: For many people, knowing their genetic status — even if the news is challenging — is preferable to the ongoing anxiety of not knowing.
• Informed decision-making: A positive result empowers individuals to make evidence-based decisions about screening frequency, risk-reducing medications, and preventive surgery.
• Personalized surveillance: Carriers of BRCA mutations typically benefit from annual MRI in addition to mammography, beginning at age 25–30 rather than 40–50. Earlier, more intensive screening can detect tumors at earlier, more treatable stages.
• Family information: A positive result signals that first-degree relatives — children, siblings, parents — have a 50% probability of carrying the same mutation, enabling them to seek testing and appropriate surveillance.
• Access to preventive options: Options for carriers include risk-reducing medications (such as tamoxifen or raloxifene), enhanced screening, and prophylactic surgeries (such as risk-reducing mastectomy or salpingo-oophorectomy), each with well-defined risk-reduction profiles.

Limitations and Considerations

• Elevated anxiety: Some individuals experience significant psychological distress upon receiving a positive result. Pre- and post-test counseling is essential to help process this information constructively.
• Inconclusive results: Variants of uncertain significance can leave individuals in a state of prolonged ambiguity.
• Family dynamics: Sharing results can be complicated. Some relatives may not wish to know their own status. Navigating these disclosures benefits from the guidance of a genetic counselor.
• Testing does not detect all risk: Genetic factors explain only 5–12% of breast cancer cases. A negative test does not eliminate the need for routine screening based on age and other risk factors.
• Insurance and privacy: In many countries, laws such as the Genetic Information Nondiscrimination Act (GINA) in the United States protect against genetic discrimination in health insurance and employment. However, protections vary by jurisdiction and do not always extend to life or disability insurance.

Managing a Positive Result: Available Interventions

A positive BRCA result is not a sentence — it is an opportunity to act proactively. Evidence-based options include:

• Enhanced surveillance: Annual breast MRI and mammography starting at ages 25–30 for BRCA1/2 carriers; clinical breast examination every 6 months
• Chemoprevention: Tamoxifen, raloxifene, or aromatase inhibitors can reduce breast cancer risk in high-risk pre- and post-menopausal women by 30–50%
• Risk-reducing mastectomy: Can reduce breast cancer risk by approximately 90% in BRCA carriers who choose this option
• Risk-reducing salpingo-oophorectomy: Recommended for BRCA1 carriers by age 35–40; reduces ovarian cancer risk by approximately 80% and may also reduce breast cancer risk
• Lifestyle modifications: Maintaining healthy weight, limiting alcohol, regular physical activity, and avoiding exogenous hormones where possible can modestly reduce overall breast cancer risk

What helixXY Can Reveal

The helixXY genetic platform provides comprehensive genomic analysis that includes assessment of variants in BRCA1, BRCA2, PALB2, CHEK2, ATM, and other genes associated with hereditary breast and ovarian cancer syndrome. Through your helixXY report, you can:

• Discover whether you carry pathogenic or likely pathogenic variants in key breast cancer risk genes
• Receive a personalized risk profile that integrates genetic data with family history indicators
• Understand the specific implications of your results for screening and prevention planning
• Access evidence-based recommendations tailored to your genetic profile

Disclaimer

This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or a recommendation for or against genetic testing. Genetic testing decisions should always be made in consultation with a qualified physician and a certified genetic counselor. A positive genetic test result does not mean you have cancer or will develop it — risk management strategies are highly individualized.

References

• National Cancer Institute. BRCA Gene Mutations: Cancer Risk and Genetic Testing. cancer.gov, 2023.
• Kuchenbaecker KB et al. "Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers." JAMA, 2017.
• Centers for Disease Control and Prevention. BRCA Genetic Testing. cdc.gov, 2023.
• Robson ME et al. "American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility." Journal of Clinical Oncology, 2015.
• Domchek SM et al. "Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality." JAMA, 2010.